Skip to Content

Abbott Laboratories ABT

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Abbott Arrives Late to the U.S. Transcatheter Aortic Valve Replacement Party With Portico

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

While Abbott just received Food and Drug Administration approval on its Portico transcatheter aortic valve replacement device, we continue to hold tempered expectations for the product and are leaving our fair value estimate unchanged. As the fourth entrant to the lucrative U.S. TAVR market, where Edwards Lifesciences and Medtronic dominate the category, narrow-moat Abbott faces a steep uphill battle to carve out a space for itself. Boston Scientific, which was the third entrant more than two years ago, had abruptly exited the U.S. market after it failed to resolve manufacturing issues with the Lotus delivery system. Based on the solid clinical data on Lotus and the device’s distinctive repositioning feature, we thought Boston had a credible chance of penetrating the existing duopoly (though we failed to appreciate the difficulty of scaling up manufacturing). In contrast, Abbott’s Portico offers little over the Edwards Sapien and Medtronic CoreValve franchises. Instead, Portico's record on post-implant paravalvular leakage is significantly worse.

Read Full Analysis

Company Profile

Business Description

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Contact
100 Abbott Park Road
Abbott Park, IL, 60064-6400
T +1 224 667-6100
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2020
Stock Type Aggressive Growth
Employees 109,000

Related

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.